| Document |
Document Title |
|
WO/2023/053272A1 |
The disclosure provides uses of multispecific antigen-binding molecules that targets human DLL3 for the treatment of cancers.
|
|
WO/2023/054547A1 |
Provided is a novel cancer treatment method which exhibits a remarkably excellent antitumor effect with little side effects. An antitumor agent includes a biphenyl compound for use in a treatment of a subject having cancer. The treatment...
|
|
WO/2023/052517A1 |
The present invention relates to a condensation product, obtained or obtainable by the reaction of phenol, formaldehyde, sulfuric acid and urea, or a pharmaceutical composition comprising the same for use in a method for the prevention o...
|
|
WO/2023/056413A1 |
Generally, the present disclosure contemplates engineered vectors, organisms (e.g., bacteria or bacteriophage) containing the same, and methods for treating the gut of mammalian species by providing the organism containing the engineered...
|
|
WO/2023/050909A1 |
Disclosed is the use of a CGA gene as a target in the preparation of a drug for diagnosing and treating drug-resistant solid tumors. Specifically disclosed is the use of the gene and/or a protein as a target in diagnosing and treating dr...
|
|
WO/2023/052682A1 |
The invention relates to the use of an activating AR gene alteration as a biomarker for identifying prostate cancer patients who have a higher probability to be responsive to the treatment with a CYP11A1 inhibitor. The invention also rel...
|
|
WO/2023/054626A1 |
Provided is a cyclopropanamide derivative. A compound represented by formula (1) [wherein: n represents an integer of 0, 1, 2 or 3; ring A represents (1) 4-pyridyl which may be substituted with 1 to 4 substituents, or (2) phenyl which is...
|
|
WO/2023/051725A1 |
A pharmaceutical combination and use thereof. The pharmaceutical combination comprises a substance X and a substance Y. When endocrine therapy is used in combination with CDK4/6 inhibitors to treat a breast cancer that has drug resistanc...
|
|
WO/2023/045778A1 |
A self-dispersed particle system, and preparation and an application thereof. By means of the self-dispersed particle system, a combination of slightly soluble or insoluble compounds can interact without the assistance of an additional c...
|
|
WO/2023/049530A1 |
The invention described herein relates to nanoparticles and micelle constructs comprising a polykinase inhibitor and/or a chemotherapeutic agent and methods of using the same to treat cancer.
|
|
WO/2023/049721A1 |
Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders and diseases associated with metabolic disorders. For example, provided h...
|
|
WO/2023/048230A1 |
The purpose of the present invention is to provide a method having a superior anti-tumor effect. [Solution] A therapy device kit having an anti-cancer drug for inducing immunogenic cell death and an administration device capable of admin...
|
|
WO/2023/049363A1 |
Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising administering to the patient sotorasib and afatinib in amounts effective to treat the cancer.
|
|
WO/2023/048748A1 |
Compositions comprising an active agent and a decoy molecule and methods for treating pain by topically administering such compositions are described herein. The compositions may be powdered. Compositions include a decoy molecule with a ...
|
|
WO/2023/048506A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a carnitine acylcarnitine carrier (CAC) inhibitor and an anticancer agent, and an anticancer adjuvant. The composition comprising...
|
|
WO/2023/047403A1 |
Provided herein is an ophthalmic composition, comprising an aqueous solution, comprising (i) a pharmaceutically effective amount of a phosphorylcholine-tuftsin conjugate, (ii) between 0.1 and 5% weight per weight (w/w) of a viscosity enh...
|
|
WO/2023/048231A1 |
The problem of the present invention is to provide a medicine for killing tumor cells, said medicine having few side effects. The present invention provides a medicine for killing tumor cells, said medicine containing: a conjugate of a s...
|
|
WO/2023/047203A1 |
Present invention relates to combination comprising omzotirome and one or more antidiabetic agent, antihypertensive agent and/or anti-dyslipidemic agent and use of such combination for managing cardio-metabolic based chronic diseases by ...
|
|
WO/2023/048233A1 |
The present invention addresses the problem of providing a medicine that is for killing tumor cells, and that has few side effects. The present invention provides: a conjugate between a cytotoxin and a substance that binds with a target ...
|
|
WO/2023/048511A1 |
The present invention relates to: a pharmaceutical composition for preventing or treating cancer, comprising a carnitine acylcarnitine carrier (CAC) inhibitor and a carnitine octanoyltransferase (COT) inhibitor; and an anticancer adjuvan...
|
|
WO/2023/049831A1 |
The present disclosure relates to the treatment of HPV-associated cancers by small molecule PD-L1 inhibitors.
|
|
WO/2023/049075A1 |
Disclosed herein are compositions and methods for treating glioblastoma in a patient in need thereof by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo [l,5-a] pyridine) or a pharmaceutically acceptable salt thereof, and an...
|
|
WO/2023/049851A1 |
Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effectiv...
|
|
WO/2023/048125A1 |
A regenerative agent for bone tissue and lung tissue that contains a macrolide antimicrobial agent as an active ingredient. The macrolide antimicrobial agent may be one or more selected from the group consisting of erythromycin, azithrom...
|
|
WO/2023/049257A1 |
The present disclosure provides methods for treating triple negative breast cancer in a subtype of subjects in need thereof, comprising adminstering to the subjects a BET bromodomain inhibitor in combination with a PARP inhibitor.
|
|
WO/2023/047790A1 |
One purpose of the present invention is to provide a production method of a cyclic oligosaccharide by which a cyclic oligosaccharide can be efficiently synthesized. Another purpose of the present invention is to provide a novel cyclic ol...
|
|
WO/2023/048299A1 |
Provided is a regulator of cell membrane scrambling (e.g., cell membrane scrambling induced by extracellular ATP stimulation), said regulator containing at least one regulator selected from the group consisting of XK expression regulator...
|
|
WO/2023/048434A1 |
The present invention relates to a composition for treating coronavirus disease 2019 (COVID-19) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients. Specifica...
|
|
WO/2023/049862A1 |
The present invention provides a method of treating a cancer in a patient or subject in need thereof comprising administering a population of modified tumor infiltrating lymphocytes (TILs), wherein the population of TILs has been modifie...
|
|
WO/2023/042872A1 |
A combined medicament that comprises particles containing an amphiphilic polymer, in which the hydrophobic segment is a poly(hydroxy acid) and the hydrophilic segment is a polysaccharide, and a cancer antigen with an immune-activating fa...
|
|
WO/2023/044423A1 |
Provided in this disclosure are pharmaceutical formulations and kits comprising antimicrobial peptides with a basic pH, wherein the antimicrobial peptide is in combination with sodium bicarbonate. Further provided herein are methods of t...
|
|
WO/2023/042901A1 |
The present invention pertains to: a drug that is for small cell lung cancer and that contains, as an active ingredient, an insulin-like growth factor 1 receptor (IGF1R) inhibitor; and a method for determining whether or not administrati...
|
|
WO/2023/041674A1 |
The invention relates to novel compositions, combinations and methods relating to compounds which inhibit EZH2 and their uses for treating and/or preventing tumors associated with methyltransferase EZH2. More specifically the invention r...
|
|
WO/2023/043632A1 |
Methods and compositions for treating cancer (e.g., ovarian, fallopian tube, uterine, cervical, vaginal, vulvar, or peritoneal cancer) are disclosed. The methods include intermittent administration of a glucocorticoid receptor modulator ...
|
|
WO/2023/043272A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, the pharmaceutical composition comprising an intestinal organoid and a TNFα inhibitor. The combined use of the ...
|
|
WO/2023/041182A1 |
The present invention relates the compound hexanoic acid, 6-(nitrooxy)-, (1S,2E)- 3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]
-3,5- dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester (Compound (I)) effective for...
|
|
WO/2023/039969A1 |
Provided is the use of a preparation capable of regulating epigenetics of macrophages in the preparation of a drug for treating hemophagocytic lymphohistiocytosis, which belongs to the technical field of biology. According to the use of ...
|
|
WO/2023/044433A1 |
Compositions and products (e.g., kits, medical devices, medicaments), which incorporate the compositions, comprising a tetrahydrocannabinol (THC) compound and a melatonin compound are provided. Methods for treatment using the composition...
|
|
WO/2023/042314A1 |
The present disclosure provides an excellent pharmaceutical composition for treating or preventing inflammatory diseases with an immune abnormality. Provided in the present disclosure is a composition for treating or preventing inflamm...
|
|
WO/2023/040963A1 |
The present disclosure provides a novel polypeptide. Also provided is an ophthalmic composition for treating or preventing dry eye (DE) or DE associated disorders. Also provided is a method for treating or preventing DE or DE associated ...
|
|
WO/2023/039778A1 |
The present invention provides an antibody drug conjugate formulation, comprising an antibody drug conjugate or a salt thereof, a citric acid buffer solution, trehalose, sodium chloride and polysorbate 80. The antibody drug conjugate has...
|
|
WO/2023/040810A1 |
Disclosed herein is a method for the treatment or delay of progression of cancer in a subject, comprising administering to the subject in need thereof a BTK inhibitor, for example, (S) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl)...
|
|
WO/2023/042555A1 |
The present disclosure provides an excellent pharmaceutical composition for treating or preventing immunological abnormal inflammatory diseases. The present disclosure provides a composition for preventing or treating immunological abn...
|
|
WO/2023/042887A1 |
The present invention provides a pharmaceutical composition for use in treating cognitive decline. This pharmaceutical composition contains an antagonist of AMPA receptors. The present invention also provides a pharmaceutical composition...
|
|
WO/2023/042944A1 |
A composition according to the present invention can very effectively prevent, ameliorate, or treat gastric cancer, specifically intractable gastric cancer, by screening a subject with suitable generic characteristics for a drug capable ...
|
|
WO/2023/041982A1 |
The present specification provides therapeutic combinations and methods for treating cancers using combination therapy.
|
|
WO/2023/039691A1 |
A functionalized protein nanoparticle-based core-shell type assembly, a preparation method therefor, and an application thereof. The functionalized protein nanoparticle-based core-shell type assembly comprises outer functionalized protei...
|
|
WO/2023/043261A1 |
The present invention relates to a compound for enhancing anticancer effects of targeted anticancer agents and chemotherapeutic agents currently in use, and, more particularly, to: a composition comprising oligopeptide AQTGTGKT, which ex...
|
|
WO/2022/212936A9 |
The present disclosure relates to the use of suitable compounds such as cannabidiol (CBD), melatonin (MLT), acetyl-11-keto-beta-boswellic acid (AKBA), or combinations thereof for treatment of pancreatic cancer and/or similar conditions, ...
|
|
WO/2023/043217A1 |
The present invention relates to uses, in the treatment of chronic skin diseases, in particular, rosacea, of a pharmaceutical composition comprising taurodeoxycholic acid, a solvate thereof, or a pharmaceutically acceptable salt thereof.
|
